Sandbox ID Lower Respiratory Tract: Difference between revisions

Jump to navigation Jump to search
Line 266: Line 266:


===Pneumonia, Mycoplasma===
===Pneumonia, Mycoplasma===
:* Mycoplasma pneumoniae (atypical pneumonia)
:* Mycoplasma pneumoniae (atypical bacterial pneumonia)
::* Preferred Regimen:[[Azithromycin]] 500 mg PO on day 1 followed by 250 mg q24h {{or}} [[Tetracycline]] Oral: 250-500 mg q6h
::* Preferred Regimen:[[Azithromycin]] 500 mg PO on day 1 followed by 250 mg q24h {{or}} [[Tetracycline]] Oral: 250-500 mg q6h
::* Alternate Regimen: [[levofloxacin]] 750 mg IV q24h {{or}} [[moxifloxacin]] 400 mg IV q24h
::* Alternate Regimen: [[levofloxacin]] 750 mg IV q24h {{or}} [[moxifloxacin]] 400 mg IV q24h

Revision as of 20:38, 10 June 2015

Acute bacterial exacerbations of chronic bronchitis

  • Chronic bronchitis with Acute bacterial Exacerbation
  • Preferred Regimen

Bronchiectasis

Bronchiolitis

Bronchitis

Cystic fibrosis

  • Pathogen directed antimicrobial therapy
  • Bacterial
  • Pseudomonas aeruginosa
  • Preferred Regimen: Tobramycin 3.3 mg/kg q8h or 12 mg/kg IV q24h AND (Piperacillin 100 mg/kg q6h OR Ticarcillin 100 mg/kg q6h OR Ceftazidime 50 mg/kg IV q8h (to maximum of 6 gm/day))
  • Alternative Regimen: Tobramycin (3.3 mg/kg q8h or 12 mg/kg IV q24h) AND (Aztreonam 50 mg/kg IV q8h OR Tobramycin 3.3 mg/kg q8h or 12 mg/kg IV q24h) AND Imipenem 15-25 mg/kg IV q6. If Tobramycin resistant add Ciprofloxacin Oral : 500-750 mg twice daily for 7-14 days-IV 400 mg every 12 hours for 7-14 days OR Levofloxacin 750 mg every 24 hours for 7-14 days
  • Only in children: Ciprofloxacin Oral :500-750 mg twice daily for 7-14 days-IV 400 mg every 12 hours for 7-14 days AND Ceftazidime IV 500 mg to 1 g every 8 hours.
  • Staphylococcus aureus
  • Preferred Regimen (Adult)
  • IF methicillin sensitive staphylococcus aureus: Nafcillin 2 gm IV q4hs OR Oxacillin 2 gm IV q4hs
  • If methicillin resistant staphylococcus aureus: Vancomycin 15-20 mg/kg IV q8-12h OR Linezolid 600 mg po/IV q12h
  • Preferred regimen (Pediatric)
  • IF methicillin sensitive staphylococcus aureus: Nafcillin 5 mg/kg q6h (Age >28 days) OR Oxacillin 75 mg/kg q6h (Age >28 days)]]
  • If methicillin resistant staphylococcus aureus: Vancomycin 40 mg/kg divided q6-8h (Age >28 days) OR Linezolid 10 mg/kg po/IV q8h (up to age 12)
  • Burkholderia cepacia

Empyema

Influenza

Inhalational anthrax, Prophylaxis

Inhalational anthrax, Treatment

Pertussis

  • Pertussis (whooping cough)
  • Preferred Regimen
  • Alternate Regimen
Note: Clarithromycin and Trimethoprim-Sulfamethoxazole are contraindicated in children below 6 mths and 2 mths respectively

Pneumonia, Acinetobacter

  • Acinetobacter species (atypical bacterial pneumonia)

Pneumonia, Actinomycosis

Pneumonia, Anaerobes

Anaerobe (aspiration) pneumonia

Pneumonia, Aspiration pneumonia

  • Aspiration (anaerobe) pneumonia

Pneumonia, Chlamydophila

  • Chlamydophila pneumoniae (atypical bacterial pneumonia)

Pneumonia, community-acquired

  • Community acquired pneumonia
  • Empiric therapy in adults
  • (A) Outpatient treatment
  • (1) Previously healthy and no use of antimicrobials within the previous 3 months.
  • Preferred regimen : Azithromycin 500 mg PO on day 1 followed by 250 mg q24h on days 2-5 OR Azithromycin 500 mg IV as a single dose OR Clarithromycin 250 mg q12h for 7-14 days OR 1000 mg q24h for 7 days OR Erythromycin 250-500 mg q6-12h (max: 4 g/day)
  • Alternative regimen : Doxycycline 100 mg PO/IV q12h (Weak recommendation).
  • (2) Presence of comorbidities such as chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; or use of antimicrobials within the previous 3 months (in this case an alternative from a different class should be selected)
  • (B) Inpatient Therapy (in regions with a high rate (125%) of infection with high-level (minimum inhibitory concentration 16 mg/mL) macrolide-resistant Streptococcus pneumoniae)
  • (1) Non-ICU treatment
  • (2) ICU treatment
  • (C) Special Concerns
  • (1) Pseudomonas
Note : For penicillin-allergic patients, substitute the B-lactam for Aztreonam 2 g IV q6-8h (maximum 8 g/day)
  • (2) Methicillin resistant staphylococcus aureus ,Add the following to the selected regimen
  • Preferred regimen: Vancomycin 45-60 mg/kg/day divided q8-12h OR Linezolid 600 mg PO/IV q12h for 10-14 days.
  • Empiric therapy in neonates ( Age < 1 month)
  • Preferred regimen: Ampicillin 500 mg/day for 7-14 days or 750 mg/day for 5 days OR Gentamicin 400 mg/day PO/IV for 7-14 days With or without Cefotaxime 320 mg PO q24h for 5 or 7 days
Note (1) : If methicillin resistant staphylococcus aureus is suspected, add the following Vancomycin 10 mg/kg q8h
Note (2) : If Chlamydia trachomatis is suspected, add the following Erythromycin 12.5 mg/kg PO or IV qid for 14 days OR Azithromycin 10 mg/kg PO/IV on day one then 5 mg/kg PO/IV q24h for 4 days.
  • Alternate Regimen (If methicillin resistant staphylococcus aureus is suspected): Vancomycin 10 mg/kg q8h OR Linezolid 10 mg/kg q8h
  • Empiric therapy,Children (> 3 months) Outpatient Therapy
  • pathogen directed antimicrobial therapy
  • Bacterial
  • (A) Streptococcus pneumoniae
  • (1) Penicillin nonresistant; minimum inhibitory concentration < 2 mg / mL
  • (2) Penicillin resistant; minimum inhibitory concentration > 2 mg / mL
  • Preferred Regimen (Agents chosen on the basis of susceptibililty) : Cefotaxime 1 g IM/IV q12h OR Ceftriaxone 1 g IV q24h, 2 g daily for patients at risk OR levofloxacin 750 mg IV q24h OR moxifloxacin 400 mg IV q24h
  • Alternative Regimen: Vancomycin 45-60 mg/kg/day divided q8-12h (maximum: 2000 mg/dose) for 7-21 days depending on severity OR Linezolid 600 mg PO/IV q12h for 10-14 days OR Amoxicillin 875 mg PO q12h or 500 mg q8 ( 3 g/day with penicillin ,minimum inhibitory concentration 4 ≤ microgram / mL)
  • (B)Haemophilus influenzae
  • (1) Non-beta lactamase producing
  • (2) Beta lactamase producing
  • (C) Bacillus anthracis (inhalation)
  • (D) Enterobacteriaceae
  • (E)Pseudomonas aeruginosa
  • (F)Staphylococcus aureus
  • (1) Methicillin susceptible
  • (2) Methicillin resistant
  • Preferred Regimen : Vancomycin 45-60 mg/kg/day divided q8-12h (max: 2000 mg/dose) for 7-21 days OR Linezolid 600 mg PO/IV q12h for 10-14 days
  • Alternative Regimen: Trimethoprim-sulfamethoxazole 1-2 double-strength tablets (800/160 mg) q12-24h
  • (G)Bordetella pertussis
  • (H) Anaerobe (aspiration)
  • (I) Mycobacterium tuberculosis
  • Preferred Regimen:
  • Intensive phase: Isoniazid 5 mg/kg/day q24h daily for 2 months (usual dose: 300 mg/day) AND Rifampin 10 mg/kg/day daily for 2 months (maximum: 600 mg / day) AND Ethambutol 5-25 mg/kg daily for 2 months (maximum dose: 1.6 g) AND Pyrazinamide 1000 - 2000 mg / day daily for 2 months.
  • Continuation phase: Isoniazid 300 mg/day PO daily for 4 months (5 mg/kg/day) AND Rifampicin 600 mg/day PO daily for 4 months (10 mg/kg/day).
  • Alternate regimen (1):
  • Intensive phase: Isoniazid 5 mg/kg/day q24h daily for 2 months (usual dose: 300 mg/day) AND Rifampin 10 mg/kg/day daily for 2 months (maximum: 600 mg / day) AND Ethambutol 5-25 mg/kg daily for 2 months (maximum dose: 1.6 g) AND Pyrazinamide 1000 - 2000 mg / day daily for 2 months.
  • Continuation phase: Isoniazid 300 mg/day PO 3 times per week for 4 months (5 mg/kg/day) AND Rifampicin 600 mg/day PO 3 times per week for 4 months (10 mg/kg/day).
Note : Acceptable alternative for any new TB patient receiving directly observed therapy
  • Alternate regimen (2)
  • Intensive phase:Isoniazid 5 mg/kg/day q24h 3 times per week for 2 months (usual dose: 300 mg/day) AND Rifampin 10 mg/kg/day 3 times per week for 2 months (maximum: 600 mg / day) s AND Ethambutol 5-25 mg/kg (maximum dose: 1.6 g) 3 times per week for 2 months AND Pyrazinamide 1000 - 2000 mg / day 3 times per week for 2 months.
  • Continuation phase: Isoniazid 300 mg/day PO 3 times per week for 4 months (5 mg/kg/day) AND Rifampicin 600 mg/day PO 3 times per week for 4 months (10 mg/kg/day).
Note : Acceptable alternative provided that the patient is receiving directly observed therapy and is not living with HIV or living in an HIV prevalent setting.
  • (J) Yersinisa pestis
  • Atypical bacteria
  • (A) Mycoplasma pneumoniae
  • (B) Chlamydophila pneumoniae
  • (C) Legionella species
  • (D)Chlamydophila psittaci
  • Preferred Regimen: Tetracycline 250-500 mg PO q6h
  • Alternate Regimen: Azithromycin 500 mg PO on day 1 followed by 250 mg q24h
  • (E) Coxiella burnetii
  • Preferred Regimen: Tetracycline 250-500 mg PO q6h
  • Alternate Regimen: Azithromycin 500 mg PO on day 1 followed by 250 mg q24h
  • (F) Francisella tularensis
  • (G) Burkholderia pseudomallei
  • (H) Acinetobacter species
  • Viral
  • Influenza virus
  • Preferred Regimen: Oseltamivir 75 mg PO q12h for 5 days (initiated within 48 hours of onset of symptoms) OR Zanamivir Two inhalations (10 mg total) q12h for 5 days (Doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours)
  • Fungal
  • (A) Coccidioides species
Note: No therapy is indicated for uncomplicated infection, treat only if complicated infection
  • (B) Histoplasmosis
  • (C) Blastomycosis

Pneumonia, concomitant influenza

  • Influenza virus pneumonia
  • Preferred Regimen: Oseltamivir 75 mg PO q12h for 5 days (initiated within 48 hours of onset of symptoms) OR Zanamivir Two inhalations (10 mg total) q12h for 5 days (Doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours)

Pneumonia, Cytomegalovirus

Pneumonia, Haemophilus Influenza

  • Haemophilus influenzae pneumonia
  • (1) Non-beta lactamase producing
  • (2) Beta lactamase producing

Pneumonia, health care-associated

Pneumonia, hospital-acquired

  • No Risk Factors for multi drug resistance
  • Presence of Risk Factors for multi drug resistance
Note (1) : Trough levels for gentamicin and tobramycin should be less than 1 g/ml, and for amikacin they should be less than 4-5 g/ml.
Note (2) : Trough levels for vancomycin should be 15-20 g/ml

Pneumonia, Klebsiella

Pneumonia, Legionella

  • Legionella pneumonia (atypical bacterial pneumonia)

Pneumonia, Lung abscess

Pneumonia, Meliodosis

Pneumonia, Moraxella catarrhalis

Pneumonia, Mycoplasma

  • Mycoplasma pneumoniae (atypical bacterial pneumonia)

Pneumonia, neutropenic patient

Pneumonia, Nocardia

Pneumonia, post-influenza

Pneumonia, Pseuodomonas

  • Pseudomonas aeruginosa pneumonia

Pneumonia, Staphylococcus aureus

  • Staphylococcus aureus pneumonia
  • (1) Methicillin susceptible
  • (2) Methicillin resistant
  • Preferred Regimen : Vancomycin 45-60 mg/kg/day divided q8-12h (max: 2000 mg/dose) for 7-21 days OR Linezolid 600 mg PO/IV q12h for 10-14 days
  • Alternative Regimen: Trimethoprim-sulfamethoxazole 1-2 double-strength tablets (800/160 mg) q12-24h

Pneumonia, Stenotrophomonas

Pneumonia, Streptococcus pneumoniae

  • Streptococcus pneumoniae
  • (1) Penicillin nonresistant; minimum inhibitory concentration < 2 mg / mL
  • (2) Penicillin resistant; minimum inhibitory concentration > 2 mg / mL
  • Preferred Regimen (Agents chosen on the basis of susceptibililty) : Cefotaxime 1 g IM/IV q12h OR Ceftriaxone 1 g IV q24h, 2 g daily for patients at risk OR levofloxacin 750 mg IV q24h OR moxifloxacin 400 mg IV q24h
  • Alternative Regimen: Vancomycin 45-60 mg/kg/day divided q8-12h (maximum: 2000 mg/dose) for 7-21 days depending on severity OR Linezolid 600 mg PO/IV q12h for 10-14 days OR Amoxicillin 875 mg PO q12h or 500 mg q8 ( 3 g/day with penicillin ,minimum inhibitory concentration 4 ≤ microgram / mL)

Pneumonia, Tularemia

  • Francisella tularensis pneumonia

Pneumonia, Yersinia pestis

  • Yersinisa pestis pneumonia